Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?

E-ISSN： 1875-533x|21|10|1171-1187

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.10, 2014-04, pp. : 1171-1187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoamine Oxidase B Inhibitors in Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Combating psychosis in Parkinson’s disease patients: the use of antipsychotic drugs

By Chou Kelvin L Fernandez Hubert H

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 339-349

Informa Healthcare

Access to resources Recommend Favorite

Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease

By Benabou Reina Waters Cheryl

Expert Opinion on Drug Safety, Vol. 2, Iss. 3, 2003-05 ,pp. : 263-267

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinsons Disease

By Kaakkola S.

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Parkinson’s Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors

Current Drug Metabolism, Vol. 17, Iss. 5, 2016-06 ,pp. : 513-518

Bentham Science Publishers

Access to resources Recommend Favorite